Navigation Links
Timing for clinical trials for stem cell therapy in spinal cord injuries is right

Regenerative medicine in spinal cord injuries (SCI) is proving to help the human body create new cell and nerve connections that are severed during this type of injury. In a review of current scientific research for stem cell treatment in SCI published this month in the Springer journal Neurotheraputics, Dr. Michael Fehlings and Dr. Reaz Vawda from the Krembil Neuroscience Centre, Toronto Western Hospital in Ontario, Canada, provide evidence that supports researchers moving beyond the lab to conduct human clinical trials for stem cells.

Spinal cord injuries remain one of the most difficult conditions to overcome. Despite the advances made in surgical interventions, drugs and rehabilitation programs, the cascade of damage that ultimately affects the body at the cellular level cannot be reversed.

Stem cell research brings tremendous hope to those who remain paralyzed after such a devastating injury. But according to Dr. Fehlings, patients are not able to realize the potential benefits of stem cell therapy because research is largely stuck in the laboratory.

"With the exception of a few clinical trials, current research is stalled at the animal model stage," said Dr. Fehlings. "Scientists from around the world have demonstrated as much as they can in lab models that stem cells have an impact on spinal cord injuries and can be transplanted into patients. Now we need the support and coordination of regulatory bodies to move this science forward."

The study critically evaluates 11 different cell types/sources and the evidence justifying their use. For example, BMSCs (Bone marrow stromal cells ) have an established safety record, as well as a beneficial effect after thoracic SCI. Glial restricted progenitors (GRPs) and oligodendrocytic progenitors (OPCs) are described to have a track record that favours the continuation of more clinical trials and Neural Progenitor Cells (NPC), of which one line of immortalized foetal NPCs has been subjected to extensive pre-clinical safety testing, may have potential benefits.

Spinal cord injuries not only cause life-long disability and carry major psychological effects, injuries to the cervical spine (neck) have a mortality rate of 10 percent in the first year following injury and an expected lifespan of only 10 15 years post injury.

Some of the evidence for increasing and expanding clinical trials from the study includes:

  • There are more than a dozen recently completed, ongoing or recruiting cell therapy clinical trials for SCI.
  • No experimental mode, rodent or otherwise, will completely mimic the human condition and it is an unrealistic hurdle for all pre-clincial findings to be validated in animals.
  • There are substantial pre-clinical and earlier clinical safety studies of satisfactory quality and reliability carried out so far to justify the immediate translation into the clinic.
  • Advances in the application of regenerative neuroscience to SCI can only be made with an investigative approach that balances excellent preclinical research with rigorous ethical clinical trials.

"At this time, a strong patient advocacy base would likely help provide momentum to help translate current research into clinical applications," said Dr. Fehlings. "Moving forward, all clinical trails must involve peer-reviewed assessment, regulation, independent monitoring, duplication, transparency and accurate record keeping of the every step of the process."

Dr. Fehlings acknowledges that no clinical intervention is 100 percent risk free and uses the examples of other novel therapies such as bone marrow transplantation and the polio vaccine to illustrate how science has forged ahead successfully, despite setbacks along the way.


Contact: Nadia Daniell-Colarossi

Related medicine news :

1. Content, Timing of TV Can Take Toll on Kids Sleep
2. For Young Kids With Pneumonia, Timing of Antibiotic Critical: Study
3. Healthy Brain Development May Be a Matter of Timing
4. Genes link puberty timing and body fat in women
5. Concentration, timing and interactions are key when it comes to dietary compounds
6. Penn-developed online informed consent tool could boost number of patients in cancer clinical trials
7. European Journal of Heart Failure publishes new randomized controlled clinical study of RESPeRATE
8. Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds
9. Abiraterone acetate improves fatigue in prostate cancer patients, says international clinical trial
10. TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
11. John Theurer Cancer Center among first clinical trial sites to join landmark MMRF study
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: